ABMD Abiomed Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABMD

Price (delayed)

$265.25

Market cap

$11.99B

P/E Ratio

57.66

Dividend/share

N/A

EPS

$4.6

Enterprise value

$11.78B

Sector: Healthcare
Industry: Medical Devices
Website: http://www.abiomed.com/

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has ...

Highlights

ABMD's quick ratio is up by 26% since the previous quarter and by 21% year-on-year
Abiomed's equity has increased by 19% YoY and by 7% from the previous quarter
ABMD's EPS is up by 31% since the previous quarter but it is down by 6% year-on-year
The net income has grown by 31% from the previous quarter but it has contracted by 6% YoY
The company's gross profit fell by 4.5% YoY
ABMD's gross margin is down by 2.4% year-on-year

Key stats

What are the main financial stats of ABMD
Market
Shares outstanding
45.19M
Market cap
$11.99B
Enterprise value
$11.78B
Valuations
Price to earnings (P/E)
57.66
Price to book (P/B)
10.11
Price to sales (P/S)
14.9
EV/EBIT
43.59
EV/EBITDA
40.24
EV/Sales
14.68
Earnings
Revenue
$802.86M
EBIT
$270.32M
EBITDA
$292.84M
Free cash flow
$246.05M
Per share
EPS
$4.6
Free cash flow per share
$5.46
Book value per share
$26.25
Revenue per share
$17.8
TBVPS
$27.71
Balance sheet
Total assets
$1.33B
Total liabilities
$145.57M
Debt
$0
Equity
$1.18B
Working capital
$611.41M
Liquidity
Debt to equity
0
Current ratio
6.81
Quick ratio
5.84
Net debt/EBITDA
-0.69
Margins
EBITDA margin
36.5%
Gross margin
80.8%
Net margin
25.9%
Operating margin
27.9%
Efficiency
Return on assets
16.7%
Return on equity
18.9%
Return on invested capital
30.3%
Return on capital employed
22.1%
Return on sales
33.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABMD stock price

How has the Abiomed stock price performed over time
Intraday
-1.1%
1 week
0.54%
1 month
4.08%
1 year
37.99%
YTD
55.49%
QTD
-4.26%

Financial performance

How have Abiomed's revenue and profit performed over time
Revenue
$802.86M
Gross profit
$648.77M
Operating income
$223.71M
Net income
$207.82M
Gross margin
80.8%
Net margin
25.9%
The net income has grown by 31% from the previous quarter but it has contracted by 6% YoY
ABMD's net margin is up by 30% since the previous quarter but it is down by 3.7% year-on-year
The company's operating income fell by 10% YoY
Abiomed's operating margin has decreased by 8% YoY

Growth

What is Abiomed's growth rate over time

Valuation

What is Abiomed stock price valuation
P/E
57.66
P/B
10.11
P/S
14.9
EV/EBIT
43.59
EV/EBITDA
40.24
EV/Sales
14.68
ABMD's EPS is up by 31% since the previous quarter but it is down by 6% year-on-year
ABMD's P/E is 25% below its 5-year quarterly average of 77.3 but 20% above its last 4 quarters average of 48.2
ABMD's P/B is 23% below its 5-year quarterly average of 13.1 but 19% above its last 4 quarters average of 8.5
Abiomed's equity has increased by 19% YoY and by 7% from the previous quarter
The price to sales (P/S) is 30% higher than the last 4 quarters average of 11.5 but 2.6% lower than the 5-year quarterly average of 15.3
The company's revenue fell by 2.1% YoY

Efficiency

How efficient is Abiomed business performance
Abiomed's ROA has increased by 26% from the previous quarter but it has decreased by 19% YoY
ABMD's return on sales is up by 25% since the previous quarter but it is down by 2.6% year-on-year
ABMD's return on equity is up by 25% since the previous quarter but it is down by 19% year-on-year
The ROIC has grown by 22% from the previous quarter but it has contracted by 13% YoY

Dividends

What is ABMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABMD.

Financial health

How did Abiomed financials performed over time
ABMD's quick ratio is up by 26% since the previous quarter and by 21% year-on-year
Abiomed's current ratio has increased by 21% from the previous quarter and by 18% YoY
ABMD's debt is 100% smaller than its equity
Abiomed's equity has increased by 19% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.